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Abstract: Mitochondria are the main fascinating energetic source into the cells. Their number,
shape, and dynamism are controlled by the cell’s type and current behavior. The perturbation
of the mitochondrial inward system via stress response and/or oncogenic insults could activate
several trafficking molecular mechanisms with the intention to solve the problem. In this review,
we aimed to clarify the crucial pathways in the mitochondrial system, dissecting the different metabolic
defects, with a special emphasis on hematological malignancies. We investigated the pivotal role of
mitochondria in the maintenance of hematopoietic stem cells (HSCs) and their main alterations that
could induce malignant transformation, culminating in the generation of leukemic stem cells (LSCs).
In addition, we presented an overview of LSCs mitochondrial dysregulated mechanisms in terms of
(1) increasing in oxidative phosphorylation program (OXPHOS), as a crucial process for survival and
self-renewal of LSCs,(2) low levels of reactive oxygen species (ROS), and (3) aberrant expression of
B-cell lymphoma 2 (Bcl-2) with sustained mitophagy. Furthermore, these peculiarities may represent
attractive new “hot spots” for mitochondrial-targeted therapy. Finally, we remark the potential of the
LCS metabolic effectors to be exploited as novel therapeutic targets.
Keywords: mitochondria; mitochondrial dysfunction; oxidative phosphorylation program; reactive
oxygen species (ROS); apoptosis; leukemia; hematopoietic stem cell; leukemic stem cell; mitophagy;
mitochondrial targeted therapy
1. Introduction
Defined in biological vocabulary, mitochondria are “Perpetuum mobile” of the cell and its
source of energy. However, speaking philosophically, mitochondria are “cells” in the cell itself,
a compartmentalized “small organisms” with their own deoxyribonucleic acid (DNA). As specified
by endosymbiotic theory [1], they originate from prokaryotic cells—alpha-proteobacteria, which
during the evolution were imbibed by eukaryotic cells [2]. The truth of this theory is sustained
by the fact that mitochondria contain their own genetic material, a circular genome that represents
mitochondrial DNA (mtDNA), also encoding proteins [3–5]. During their maximal activity, they
are elongated and interconnected organelles; consequently, the shape of the mitochondria reveals
the degree of cell energetic activity [6–8]. Although they have many aspects of autonomy, their
biogenesis depends on the inevitable cooperation with other organelles, especially with the endoplasmic
reticulum (ER). This structural-physiological unit of communication between mitochondria and the
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ER is named mitochondria-associated membranes (MAM). Through this communication fissure
with ER, mitochondria import essential resources that serve as dynamic sustainability of their
structures, such as lipid precursors like phosphatidylserine, phosphatidic acid, phosphatidylcholine,
phosphatidylinositol, and sphingolipids [9]. Finally, alongside the unique structural and metabolic
characteristics, mitochondria are the major cause of reactive oxygen species (ROS) production in
response to cellular stress and this event can induce cellular damage. Thus, a quality check process
is crucial to prevent the onset of several pathological conditions. Within this scenario, the interplay
between mitochondrial biogenesis and mitochondrial degradation through mitophagy is crucial for
mitochondrial homeostasis.
In this comprehensive review, we aimed through an attentive examination of the processes along
with the axis normal function—dysfunction to highlight which are the most considerable molecular
mechanisms responsible for mitochondrial dysfunction, with particular regard to hematopoietic and
leukemic stem cells. In addition, we discuss potential novel treatment alternatives arising from the
latest knowledge of impaired metabolic and apoptotic pathways in different leukemic disorders.
Mitochondria: From Structure to Metabolic Pathways
Mitochondria are constituted of two membranes, which differ in terms of protein composition
and function. The outer mitochondrial membrane (OMM) separates mitochondria from the cytosol,
and the communication is maintained through porous structures, for instance, the voltage-dependent
anion channel (VDAC), which allows metabolites and other substances to pass in both directions [10].
Between the membranes, there is the intermembrane space (IMS), and the area that is bounded by
the inner mitochondrial membrane (IMM) is called the mitochondrial matrix. The IMM is the place
where the protein complexes of the respiratory chain (RC) are located. They can be seen as both
individual orsupercomplexes [11]. IMM has an intensely folded structure, thereby enlarging the
surface several times and creating the well-known cristae, one of the main features of mitochondria as
organelles [12]. In fact, cristae are much more than just a physical phenomenon in the mitochondrial
picture: they undergo an intensive remodeling process, changing the depth of their folds depending on
cell activity. During the pro-apoptotic process, mediated by the pro-apoptotic BCL-2 family proteins,
cristae undergo intensive remodeling in order to increase the cytochrome c infusion [13]. The shape of
the cristae along with the IMM also depends on the energetic status of the cell. During intensive energy
production, their twisting can multiply in order to provide more efficient electronic transport [14].
Along the membrane, the electron transport over RC and protein pumping into the IMS
generates the proton gradient-potential gradient, thus achieving a process of oxidative phosphorylation
(OXPHOS), the final stage of cellular respiration [11,12,15]. The electrons that enter the RC originate
from the Krebs cycle, also known as the tricarboxylic acid (TCA) cycle. The TCA cycle—eight series of
enzymatic reactions—starts with the reaction between acetyl-CoA and oxaloacetate forming citrate.
Reduced cofactors, nicotinamide adenine dinucleotide (NADH), and flavin adenine dinucleotide
(FADH2) are released during these subsequent reactions. In the final reaction of the cycle, the malate
is converted to oxalacetate by transferring two electrons to NADH, and the oxalacetate is ready to
re-enter the cycle. The electrons that are generated in the TCA cycle are carried by NADH and FADH2
and then passed to the RC [15]—then, by OXPHOS of these NADH and FADH2 factors, even if with
lower efficiency if compared to Krebs cycle.
In addition to the classical pathway responsible for ATP synthesis, another important source
of acetyl-CoA is the β-oxidation of fatty acids. Although long-chain fatty acids are oxidized in
peroxisomes, short-chain fatty acids can simply diffuse through the IMM, where they are oxidized.
Free fatty acids are stored as neutral triacylglycerols (TAGs) in lipid droplets (LD) and can be taken up
into mitochondria for energy reserve. The process initiates with the action of the adipose triacylglycerol
lipase (ATGL) and hormone-sensitive lipase by which fatty acids are released from TAG. After a series
of catabolic processes, the fatty acids and degraded to acetyl-CoA, by providing substrate TCA and
EC, even if with lower efficiency if compared to the Krebs cycle.
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Besides energy production, mithochondria also have vital roles in numerous cellular processes,
including apoptotic activation and cell death, maintenance of ion homeostasis especially calcium,
synthesis of phospholipids (for example phosphatidylethanolamine, phosphatidylglycerol, and
cardiolipin), of amino acids and heme, among others [16,17].
The mitochondria demonstrate a high demand for lipid precursors since they have two organelle
membranes and are involved in the final refinement of the membranes’ lipids. The communication with
ER through MAM is a two-way trade and the amplest phospholipids of the cells, phosphatidylcholine,
phosphatidylethanolamine, and phosphatidylserine cannot be synthesized without well defined,
two-way trading. For example, the phosphatidylserine is first produced by the enzymatic reaction in
the ER and then transferred to the IMM to be converted into phosphatidylethanolamine. Otherwise,
phosphatidylethanolamine, in order to be modified into phosphatidylcholine, must be relocated to the
ER, where the enzymes for this reaction take place.
Cardiolipin (CL) is contemplated as the most important mitochondria-specific phospholipid due
to its role in mitochondrial morphology, cellular signalling, RC and metabolism as in a mitochondrial
life cycle. The IMM is the place where the biosynthesis of CL is performed. Further to this, many
studies have investigated the tissue-specific profile of the CL as well as the factors that could influence
these differences [18]. Because of its unique structure and localization, CL has an important role in
defining the shape and folding of the IMM, the function of RC and membrane potential gradient as
well as the modulation of fission and fusion pathway [19,20].
Finally, mitochondria modulate amino acid homeostasis according to the cellular needs and to
the changes in nutrient availability, in order to survive [21]. Thus, mitochondrial metabolism can
be modulated even from amino acid availability. Unlike bacteria and plants, mammals have the
peculiarity to synthesize in the cytosol, in an ATP-requiring reaction, 11 of 20 aminoacids, named
essential aminoacids. Among them, we remembered glutamate, glutamine, proline, and arginine
that are directly formed from the Krebs cycle intermediate product α-ketoglutarate. Aspartate
and asparaginesreadily formed by mitochondria provided oxaloacetate, while glycine, cysteine,
and serineare made from intermediates formed by glycolysis [21]. Besides amino acid synthesis,
mitochondria have a central role in amino acid metabolism in order to produce precursors and
substrates (carbon backbone of all amino acids) for TCA cycle intermediates, which culminate in the
generation of ATP [22]. Indeed, dysfunction of mitochondrial enzymes involved in the metabolic
pathways of amino acids is a driver factor for over 40 known disorders in humans.
2. A General Overview of Respiratory Chain Dysfunctions and Apoptotic Dysregulations
Mitochondrial diseases are usually a various group of hereditary aging-related disorders with
diverse clinical manifestations on multiple organ systems. In general, the etiology of mitochondrial
diseases can be summarized as malfunctioning of the respiratory chain and dysregulation of cell
growth, proliferation, and cell survival due to the presence of dysfunctional proteins encoded by
mitochondrial or nuclear genetic material [23]. The list of diseases in which mitochondrial dysfunctions
represent the major underlying cause or make a significant contribution is broad, and it includes several
neurodegenerative and cognitive diseases, certain myopathies, endocrine diseases, such as diabetes
mellitus, cardiovascular and renal diseases, as well as many cancer types, including the hematological
malignancies [24]. The complex link between leukemogenesis and mitochondrial dysfunction can
also be seen in the use of certain drugs, such as the antibiotic chloramphenicol. Indeed, prolonged
treatment with chloramphenicol, a known inhibitor of bacterial and mitochondrial protein synthesis,
induces dysplastic changes in the bone marrow, sideroblastic anemia and aplastic anemia, which
are typical features observed in myelodysplastic syndromes (MDS) and in acute myeloid leukemia
(AML) [25]. Indeed, in terms of energy and mitochondria activity, erythropoiesis is one of the most
demanding processes in the body. Thus, it is not surprising that anemia is the first effect to be observed
when mitochondria are dysfunctional. Furthermore, chloramphenicol causes inhibition of apoptosis,
mitochondrial translation, ATP synthesis, respiratory activity, and cell growth. These events increase
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mitochondrial stress resulting in altered cellular metabolism and activation of further processes, which
lead to the onset of leukemia [25–27].
2.1. Disease-Associated Defects in Oxidative Phosphorylation
The electron transport chain (ETC) is a term that describes the complex processes of simultaneous
electronic transfer and redox reactions across four protein complexes (I–IV) embedded within the
IMM. Mutations in genes that encode proteins and enzymes of the ETC lead to an irregular process of
electron transport, inefficient oxidative phosphorylation, and energy cell deficit [28,29].
Recently, 200 AML patients from the Cancer Genome Atlas (TCGA) dataset were analyzed,
showing the presence of 8% of patients with mutations in one or more of ETC complexes genes. It was
found that the majority of these mutations affected Complex IV; moreover, they occur more frequently
in older patients and they are associated with TP53 mutations and worse survival rates [30].
Complex I or NADH-coenzyme Q oxidoreductase is a large protein complex built of 46 subunits [31],
and NADH dehydrogenase (ND) subunits 1 to 7 (ND1–ND7) are mitochondrially encoded.
The implications of Complex I in human pathology are investigated through its ability, together
with Complex III, to produce ROS that are toxic to lipids, proteins, and nucleic acids [32]. Some of these
ROS are produced during normal cellular metabolism and they have an endogenous origin, mainly
by Complex I and III, but there are ROS engendered due to the influence of external factors such as
radiation, UV radiation, and heavy metals [33,34]. Although normal ROS production levels play an
important role in maintaining proper intracellular signaling, increased levels of ROS production or
dysfunction of the cell’s antioxidant defense mechanisms may be the initial trigger factor for a wide
range of diseases [35,36]. Functional abnormalities in complex I, which are a consequence of gene
mutations (nuclear or mtDNA), lead to increased ROS production and a decrease of the energetic
cellular capacity [32,37].
Following this line of events, many studies have shown a link between dysfunctional mitochondrial
metabolism, oxidative stress, and some chronic degenerative diseases [38–40], for example, the Leber
hereditary optic neuropathy [41]. Recent studies, sublimated in one significant meta-analysis, indicate
a strong correlation between the etiopathogenesis of Parkinson’s and Alzheimer’s disease and complex
I and/or complex IV dysfunction [42,43]. A certain association between mitochondrial impairment and
major psychiatric disorders has also been confirmed [43]. ND genes code the ND subunits of Complex
I, and they are one of the most common mutations related to the Complex I functional impairment.
ND mutations were also described in AML patients correlating with shorter overall survival [29,44].
Complex II or succinate dehydrogenase (SDH), besides being part of the respiratory transport
chain, contemporaneous is a part of the citric acid cycle. It is built of four subunits (SDHA-D), and
unlike other mitochondrial complexes, all four of the subunits are nuclear genes encoded [34,45].
Due to its role in apoptosis and certain types of tumorigenesis [46,47], its pathological implications
are related to some neurological diseases such as Leigh syndrome and Huntington’s disease [48,49].
Recently, cysteine depletion has proven effective to target AML cells through a significant impairment
of glutathione synthesis, leading to a reduction in glutathionylation of SDHA that, in turn, affects the
ETC II activity [32,50].
The next junction in the respiratory chain is complex III or coenzyme Q–cytochrome c reductase.
Complex III is an oxidoreductase enzyme that reduces ubiquinone to ubiquinol, which is why the
reactions in complex III are also called the ubiquinone cycle [51]. The clinical implications of complex III
are closely related to the production of ROS in association with complex I which conjointly contributes to
the explanation of the free radicals’ theory of aging [52]. Moreover, a recently published immunological
study proved the essential role of mitochondrial complex III in the suppression of regulatory T cells [53].
There is quite a bit of scientific data on the involvement of complex III in human pathology, but we
will mention only the most frequent ones. Among these disorders are GRACILE (growth retardation,
aminoaciduria, cholestasis, iron overload, lactic acidosis) and Björnstad syndrome; both of them are
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prompted by a mutation in the mitochondrial chaperon gene BCS1L [45,54]. No significant association
between Complex III mutations and overall survival in leukemia was found so far.
The enzyme cytochrome c oxidase (COX), or respiratory complex IV, is a membrane protein with
a complex structure. Constructed of 14 subunits, it is the final link of the respiratory chain that works
closely with cytochrome c [55]. A number of external factors, such as cyanide and CO, affects the
activity of complex IV, thereby reducing or completely blocking its participation in electron transfer.
This disables the process of oxidative phosphorylation which actually means energy deficiency and
cell death [56].
COX deficiency can exist as complete dysfunction of the whole complex or its individual parts,
depending on whether the mutations affect the mitochondrial or nuclear genome. Some of the
clinical manifestations associated with COX deficiency have been described previously, together with
complex I, and they are neonatal tubulopathy, Leigh syndrome, neonatal-onset hepatic failure and
encephalopathy, early-onset cardiomyopathy, Alpers–Huttenlocher like disease, ataxia, and muscle
hypotonia [57,58].
From the hematological point of view, in MDS pathology, the reduction in expression of
mitochondrial genes, and mutations in subunits 1 and 2 of cytochrome c-oxidase (COI and COII)
are well established. They seem to represent the main cause of respiratory chain defect, leading to
a reduction in conversion from Fe3+ to Fe2+ and consequently to sideroblastic anemia [59]. Moreover,
the 16% of AML patients with non-synonymous COII mutations exhibit worse prognosis and shorter
disease-free survival (DFS), especially in normal cytogenetics AML (CN-AML) patients. On the whole,
these experimental findings might be exploited as novel prognostic markers to be explored in this
subset of AML patients [60]. The co-occurrence of mutations in ETC complex I and IV further increase
the adverse prognosis, with a significant reduction in overall survival [30].
Interestingly, D-2-hydroxyglutarate (2-HG) accumulation, a typical feature in the isocitrate
dehydrogenase (IDH) AML mutated cells, negatively impact complex IV with a significant reduction
of COX enzymatic activity, when compared to IDH wild type AML cells. Moreover, combinatory
therapy targeting mitochondrial oxidative phosphorylation significantly improves the efficacy of
IDH mutant inhibitors in AML patients [61]. Mutations in IDH genes result in alteration of cellular
metabolism, impaired cell adaptation mechanisms, epigenetic dysregulation, and they are associated
with a poor prognosis in patients with AML [62–65]. The IDH enzymes exist in three homodimeric
isoforms, IDH1, IDH2, and IDH3. Both IDH1 and IDH2 play an enzymatic role in the TCA cycle,
converting isocitrate to α-ketoglutarate (α-KG). Reduced nicotinamide adenine dinucleotide phosphate
(NADPH) is the product of this reaction. IDH1 has cytoplasmic localization, IDH3 as well as IDH2
exhibit a mitochondrial localization, and perform their function by favoring energy production in
mitochondria [58]. Mutated IDH1 and IDH2 acquire neomorphic activity that converts α-KG to
2-HG, which has oncogenic properties and acts as a competitive inhibitor of enzymes involved in
α-KG metabolism.
Finally, IDH exerts its influence on DNA methylation and histone modification. An example is the
inhibitory effect on TET2 protein, which plays a role in epigenetic regulation [66]. This correlation has
been well established in a study on AML patients, where global hypermethylation and loss of TET2
function has been observed [67].
2.2. Apoptosis Dysregulation Increases the Propensity to Malignant Transformation
Apoptosis—the programmed death of the cells—is a process characterized by a variety of cellular
events, involving many components that are linked and dependent on each other at multiple levels,
and able to directly or indirectly activate/inhibit certain molecular pathways [68]. Although both
apoptotic (intrinsic and extrinsic) activation pathways have the same purpose and common endpoint
(caspases), here we will only address the intrinsic pathway of apoptosis regulation because it directly
involves the mitochondrial compartment. Given the fact that malignant neoplasms carry abnormal
cell proliferation, detailed insight into the molecular map of apoptosis with certainty may answer
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many questions related to cancer etiology and therapy. Going backward in the scientific history,
a milestone observation about the association between apoptosis and cancer formation is given
by Weinberg et al. [69], when they unquestionably stated that one of the main characteristics of
malignant transformation is the escaping from cell death—the hallmark of cancer, which further leads
to uncontrolled cell proliferation.
By way of illustration, ineffective hematopoiesis induced by excessive apoptosis of hematopoietic
precursors is one peculiar feature in MDS. During the early stage of MDS, apoptosis is increased
through overexpression of TNFα, Fas-ligand, and TRAIL. Subsequently, the disease progresses
because malignant cells acquire the ability to induce a shift in favor of anti-apoptotic and proliferative
signals, escaping the pro-apoptotic pathways, with subsequent possible progression in acute myeloid
AML [70,71].
In this context, the BCL-2 family proteins represent the key elements in the majority of the
deregulated hematological apoptotic processes. These proteins were named after the discovery of the
founding member B-cell lymphoma 2 BCL-2 protein, which is encoded by the BCL2 gene. This gene
was described for the first time as the second protein member in the B-cell lymphomas portrayed
with the translocation t(14;18) [57,72,73]. Decades later, the scientific community, bearing in mind this
assumption, developed a whole range of scientific investigations, having as their core observation
the apoptotic dysregulation and malignant malformation. A number of factors, such as oxidative
stress, DNA damage, high cytosolic calcium concentration, and oncogene activation, may initiate the
mitochondrial pathway of apoptosis. The overall regulation of this pathway is mediated by the BCL-2
family proteins, which are divided into two major groups, pro-apoptotic (for example BAX, BAK,
PUMA) and anti-apoptotic (for example BCL-2, BCL-XL, MCL-1) proteins [74,75].
Anti-apoptotic proteins like Bcl-2 and Bcl-xL were markedly upregulated in different types of
leukemia malignancies, especially in more advanced MDS and in newly diagnosed AML, when
compared to normal samples or AML patients under complete remission [76]. Their expression
correlates with worse prognosis, while higher levels of proapoptotic proteins were associated with
a lower risk of relapse or leukemic transformation [77]. Overexpression or mutations of BCL-2
allow chemoresistance to hematological malignancies. Nevertheless, other studies did not identify a
significant association of BCL2 overexpression with prognosis, suggesting that Bcl-2 in AML blasts may
not be a useful single factor affecting prognosis [76]. Interestingly, the high levels of BCL-2 identified
in leukemic stem cells (LSCs) provide a novel strategy to target the quiescent LSC population. In this
regard, in 2016, the specific BCL-2 inhibitor venetoclax (ABT-199), was approved by the Food and Drug
Administration (FDA) for relapsed Chronic lymphocytic leukemia (CLL) with 17p deletion. Nowadays,
venetoclaxis also used in AML patients. Another important player in leukemia apoptosis dysregulation,
also crucial for hematopoietic development, is the anti-apoptotic MCL-1 protein. Its deregulated gene
expression is associated with several hematological malignancies including AML, multiple myeloma
(MM), and B-cell acute lymphoblastic leukemia (B-ALL). Gene deregulation is correlated with relapse
and resistance to targeted therapies like venetoclax [78].
Integral portraiture of the connection between apoptosis and carcinogenesis is Cytochrome c
and its role in caspases activation [79]. Pro-apoptotic factors increase the permeability of the OMM
for cytochrome c, while the anti-apoptotic factors do the opposite [80]. Apoptosis begins with
homo-oligomerization of BAK and BAX proteins, which create pores on the outer mitochondrial
membrane in direct interaction with BH3-only proteins, the process thus termed ‘mitochondrial
priming’ [81,82]. Throughout the process, the interaction of BH3-only proteins with pro-apoptotic
factors enhances their oligomerization, thus achieving sufficient size and shape to form the effector pores
on the outer mitochondrial membrane [83–85]. The anti-apoptotic factors manifest their activity by
either binding to BH3-only protein and preventing its interaction with BAK and BAX or blocking already
activated forms of BAX and BAK [81,86]. Venetoclax and several other promising BH3-mimetic drugs
have been developed in order to inhibit the BH3-only proteins sequestration mediated by Bcl-2 and to
promote apoptosis only via BAX-BAD-BH3 interaction. Within this scenario, Edlich et al. described how
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BAX localization determines the predisposition to apoptosis in human AML. Indeed, high BAX level in
the blasts mitochondria correlates with increased sensitivity to chemotoxic stress, while high cytosolic
BAX level is associated with cellular resistance to chemotherapies, suggesting BAX localization as
a new important prognostic marker [87]. Reyna et al. develop BTSA1, a pharmacologically optimized
BAX activator, which leads to sustained BAX-mediated apoptosis in leukemia cell lines and in AML
xenografts, providing a novel therapeutic strategy in AML [88]. Thus, in conclusion, the formation of
pores on the OMM and the penetration of cytochrome c can be named as a “point of the inevitable
cell death”.
3. Mitochondria in the Hematopoietic Stem Cells: ADormant Galaxy
The two main features of stem cells are quiescence and lifelong self-renewal capacity [89].
The switch from this condition to cycling and proliferating is crucial for stem cell fate, homeostatic
preservation, tissue regeneration, and it is directly linked to mitochondrial status [90,91]. The interplay
between hematopoietic stem cells (HSC), microenvironment, and the hypoxic niche play a pivotal
role in stem cell decision since it seemed to be enough for self-renewal or commitment decision [92].
Low oxygen levels sustained the characteristic metabolic state of HSC, and pointed out the adaptation
to microenvironmental changes and plasticity property of stem cells [93]. The metabolic conditions
of HSC are low energy, low ROS, and mitochondrial dynamics [94] (Figure 1). The balance between
these features leads to the decision to remain quiescent or to differentiate, through the asymmetric or
symmetric division process [95].
3.1. Low Energy Requirement Defines Hematopoietic Stem Cells
HSCs use anaerobic glycolysis as the main energy source while OXPHOS is used when HSCsswitch
toward proliferation and differentiation [96]. Glycolysis is primarily used in order to adapt hypoxic
conditions and to meet the cellular low energy demand [97]. During this process, glucose is converted
into pyruvate and two ATP molecules are produced. The choice of glycolysis represents an HSC
protective process against high levels of ROS production occurring during the OXPHOS process, under
aerobic conditions, to produce energy via electrons transport. Specifically, glycolysis derived pyruvate
enters into the mitochondrial tricarboxylic acid (TCA) cycle to produce 36 molecules of high-energy
ATP [97]. From a biological point of view, a high level of hypoxia-inducible factor 1 (HIF-1) is a driving
force for the glycolysis program activation [98]. HIF-1 is a transcription factor activated during hypoxia,
after alpha subunit stabilization under low oxygen conditions. Subsequently, HIF1a interacts with
a constitutively expressed HIF1b subunit to form a complex able to coordinate the transcription of
genes involved in the glycolytic process [98]. Remarkably: (1) it promotes pyruvate dehydrogenase
kinase (PDK2 and 4) expression. This event is followed by phosphorylation of pyruvate dehydrogenase
(PDH) and suppression of pyruvate entrance in the TCA cycle [99]. In a knockout mice model of HIF1a,
the overexpression on PDK2 and 4 restored the HSC number by increasing in glycolysis program and
decreasing in mitochondrial metabolism, suggesting a pivotal role of HIF1-PDK axis for in vivo HSC
maintenance [100]; (2) it induces the expression of genes coding for glycolytic enzymes, including
Lactate Dehydrogenase A (LDHA) [101], Hexokinase 1 and 2 (HK1, HK2), Aldolase A and C (ALD-A,
ALD-C), Enolase alpha (ENOalpha), and Phosphoglycerate Kinase 1 (PGK1) [102]; (3) it promotes
the glucose transporters expression (GLUT1 and GLUT3) [103]. Upstream regulators of HIF1 are
mainly expressed in hematopoietic stem cells and they are extremely relevant for HSC fate. MEIS1 and
CBP/p300 interacting trans-activator 2 (CITED2) constitute the main transcriptional factor of the HIF1
gene in the HSC compartment [104,105]. In turn, they directly control glycolysis and the oxidative
stress response. Meis1−/− mice showed a significant reduction in hypoxia-related genes, long-term
HSCs exhaustion, and increasing in ROS levels [106].
Finally, fatty acid oxidation (FAO) is another alternative source of high-efficiency metabolic energy
for HSC. This mechanism was activated in early hematopoietic cells and reduced during differentiation.
FAO generates the production of NADPH and sustains ATP to counteract oxidative stress and to
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prevent ROS accumulation. A correct balance between pyruvate and beta-oxidation is crucial to
maintain HSC property and to control the asymmetric cell division. Ito et al. identified a novel
peroxisome proliferator-activated receptor δ (PPARδ)-FAO pathway as essential for the preservation
of HSC [107]. PPARδ deletion led to a decrease in the amount of ATP in HSC, while treatment with
etomoxir, a known inhibitor of mitochondrial β-oxidation, was associated with HSC exhaustion
and inability to sustain the hematopoietic compartment. Moreover, PPAR-δ has shown to positively
regulate FA oxidation by the PML-PPARδ-FAO axis [107]. Indeed, Pml−/− defective HSCs are rescued
through PPAR-δ activation, suggesting that dysfunctional PPAR-δ signaling and FAO are directly
linked to PML. Finally, FAO-dependent NADPH production has been confirmed to have a pivotal role
in the survival of leukemia cells, as described above.
3.2. Low Free Radicals Amount: A Peculiar Feature of Hematopoietic Stem Cells
It is well consolidated that OXPHOS activation is among those mainly responsible for ROS
production and for the passing into the cell cycle [86,97]. According to the metabolic demands, the cell
may decide to maintain stem features with low mitochondrial activity and low free radicals level, or to
activate differentiation, with an increase in mitochondrial number and activity, through glycolysis
or OXPHOS program, respectively [86,97]. Furthermore, ROS can damage many cellular elements,
including RNA, DNA, and proteins. These events may be dangerous especially in HSCs, thus causing
mutations harmful for maintenance of stem cell quiescence, finally leading to HSC senescence and loss
of self-renewal capacity [108]. Therefore, HSCs activate several biological processes and redox sensors
to reduce ROS damage and to avoid loss of self-renewal potential and HSC exhaustion as follows:
(1) Nuclear factor erythroid 2-Related Factor 2 (NRF2) preserves cellular redox balancing from
oxidative stress. Its stability is tightly regulated in order to ensure a very short half-life of the protein [109].
Notably, under basal unstressed condition NRF2 is recruited byKelch-like ECH-associated protein 1
(KEAP1). The complex is retained into the cytoplasm and, after CUL3-E3 ubiquitin ligase activation,
Nrf2 is rapidly ubiquitinated and degraded via proteasome [89]. In this scenario, one mechanism of
cell response to toxic metabolites generated by ROS is the increase in NRF2 stability after the KEAP1
conformation change, leading to disaggregation of the NRF2-KEAP1 complex [110]. Subsequently,
NRF2 translocates into the nucleus where it induces the transcription of several antioxidant enzymes,
after the binding to the antioxidant response element (ARE), located on the promoter regions. Indeed,
Nrf2−/− reduced significantly the expression of superoxide dismutase genes (SODs) [111].
(2) Forkhead box O3 (FoxO3) are transcription factors crucial for HSCs maintenance [112,113].
They diminish ROS mutagenesis effects by regulating the expression of some genes encoding for
detoxifying enzymes like peroxisome-located Catalase (CAT), superoxide dismutase 2 (SOD2), and the
redox enzyme sestrin3 (SESN3) [114–116]. Moreover, it reduces mitochondrial activity by inactivation
of mitochondrial respiratory chain proteins [114]. FoxO−/− HSCs mice are defective in DNA damage
repair and the expression of several anti-oxidant protein-encoding genes is significantly impaired, with
a consequent increase in ROS levels [113]. The process described above is directly led by the upstream
FoxO regulators PI3K-AKT and 5′ AMP-activated protein kinase(AMPK) signaling pathway, which
acts as energetic and oxidative stress sensors. The AKT-mediated FOXO3a inactivation modulates
ROS levels, the activation of the cycling process and the exhaustion of HSCs through a negative
control exerted on Foxo3a and a positive effect on mTORC1 [117,118]. To counteract this effect, the
Phosphatase and Tensin homolog (PTEN) antagonizes the PI3K/AKT pathway through an increase in
phosphoinositide 4,5-biphosphate (PIP2) levels thereby protecting cells against oxidative damage [119].
In turn, increased ROS levels are directly linked to phosphoinositide-3,4,5-trisphosphate (PIP3) signaling
as a result of oxidation of cysteine residues in PTEN catalytic site causing its inactivation [119]. Finally,
Pten−/− mice showed a depletion of the stem cell pool and increase in ROS level, suggesting an
overlapping action with FoxO3a in HSCs maintenance [120]. In the second axis, AMP kinase (AMPK)
positively activates FoxO3a by phosphorylation on different residues (Thr 179, Ser 399, Ser 413, Ser 555,
Ser 588, and Ser 626), leading to the expression of genes involved in stress resistance [121]. AMPK, in
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turn, activates ATP generation through glycolysis and fatty acid oxidation and directly inhibits mTORC1
activity, reducing protein synthesis [122]. Importantly, FOXO3a activation mediated by AMPK exhibits
a pro-autophagy gene expression pattern crucial to regulate dynamic mitochondrial numbers, with
Unc-51 Like Autophagy Activating Kinase 1 (ULK1) as the main factor involved [123]. However,
AMPK−/−HSC mice showed a modest dysfunction, suggesting a role of AMPK in HSCviability only
under certain stress conditions.
Finally, FoxOs activity can be modulated by deacetylation on lysine residues conducted by Sirtuin1
(SIRT1) [124]. SIRTs are NAD+-dependent lysine deacetylases proteins, localized in mitochondria
and activated by oxidative stress conditions. They are defined as metabolic sensors due to their
ability to regulate cellular stress response. In the HSC compartment, SIRT1 activation induces ROS
levels’ reduction and the increase in autophagy as well as in several anti-oxidant enzymes such as
SOD and catalase. SIRT1−/− HSC cells exhibit FoxO3a-mediated ROS level increase and quiescence
reduction [125].
(3) Ataxia-telangiectasia mutated (ATM) kinase is a tumor suppressor involved in ROS regulation
and in sustaining the hematopoietic stem cells pool [126]. It is a serine/threonine kinase, crucial for
cellular response to double-strand DNA break damage activated by several mechanisms including
accumulation of reactive metabolites [127]. ATM−/−mice showed increased ROS levels and functional
reduction of HSCs [128]. Furthermore, the main consequence of ATM inactivation is the phosphorylation
of p38 MAPK on the HSC compartment. This event induces the activation of p16, a cyclin-dependent
kinase (CDK) inhibitor, and a subsequent reduction in HSCs self-renewal capacity and enhancement
in cellular senescence [129]. Importantly, ATM is able to activate the BH3-Interacting Domain death
agonist (BID), a BCL-2 family pro-apoptotic member [130]. Its phosphorylation by ATM kinase plays
a pivotal role in maintaining the quiescence of HSCs and in protecting HSCs from oxidative stress.
All these events suggest that ATM, by mediating ROS levels, may regulate cell fate decisions through
p38 MAPK and BCL-2 proteins as downstream effectors. Finally, ATM activation by oxidative stress
induces phosphorylation of NRF1, crucial for transcription of several antioxidant enzymes, and it
mediates the phosphorylation of HIF1, with a consequent increase in HIF1 stability and activation of
stem cells maintenance machinery [131,132].
3.3. Mitochondrial Dynamics Defines Hematopoietic Stem Cells
Mitochondria functionality is related to their morphology and the term “dynamics” is rightly used
to describe the perpetual change in shape and number that in turn affects cellular reprogramming [133].
Therefore, mitochondrial high plasticity is necessary to improve cell viability, according to energy
cellular demand and ATP levels, and they are a bona fide sensors of cell bio-energetic status [133].
Fusion, fission, and mitophagy are the main events involved in mitochondrial homeostasis. In stem
cells niche ATP levels are low and mitochondria are in a basal activity state. They are localized in the
perinuclear area, and their shape is generally fragmented, with fewer cristae but functional electron
transport chain [134]. This conformation is strongly mito-fission dependent. The dynamin-related
protein 1 (DRP1) and Mitochondrial fission 1 protein (FIS1) active form represent the main proteins
responsible for this subcellular distribution pattern [134]. Impaired DRP1 and FIS1 expression induce
a significant reduction in HSCs number due to a metabolic switch from glycolysis to OXPHOS that
in turn promote a differentiating cell program [135]. It is fascinating that DRP1 and FIS1 seem to
support the asymmetric stem cell division favoring the maintenance of stem cell feature only to
daughter cells that receive more young mitochondria [136]. Lastly, a hypoxia condition activates the
mito-fission pathway to maintain stem cell features while oxidative stress and ROS increased levels
contribute to apoptosis or autophagy mito-fission dependent [137]. Along with the differentiation,
cells are characterized by a mitochondrial-diffused distribution, with a tubular and elongated shape, in
network with each other [138]. ATP levels produced via OXHPOS are high and ROS levels too. This
feature is mito-fusion dependent, and Mitofusin 1/2 (MFN1, MFN2) and Mitochondrial Dynamin Like
GTPase (OPA1) proteins are the main responsibility [139]. The MFN proteins are located in the OMMs
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while OPA1 in the IMMs. Mfn1/2 depletion reduces the mitochondrial numbers and it induces HIF1
stabilization, thus facilitating glycolysis and pluripotency program [140]. In addition, mitochondrial
fission and fusion factors reciprocally orchestrate efficient mitophagy. Mitophagy represents a crucial
mechanism in stem cell maintenance [141]. It sustains functional mitochondrial, it promotes turnover
of mitochondria, while removing those defective and it protects cells from apoptosis [141]. In addition,
mitophagy is also important to regulate mitochondrial numbers according to cellular metabolic, thus
it is essential for HSCs homeostasis. ROS high levels, by causing mitochondrial dysfunction, are
the main train force to the mitophagy-clearance process [142]. Autophagy-related genes (ATGs) are
responsible for mitophagy induction. ATG genes knockout inhibits mitophagy, induces aberrant
mitochondrial accumulation, an increase of ROS levels and of the active metabolic state which impairs
HSCs functionality [142].
Inhibition of mitochondrial fission through DRP1 deficiency increases the clearance process
leading to the loss in mitochondria numbers and culminates in cell death pathway after mitochondrial
membrane potential (∆ψm) depolarization [135]. Mito-fusion damage through MFN 1 and 2 depletion
provoke the accumulation of defective mitochondria [143]. The PTEN-induced putative kinase 1
(PINK1) and the Parkin-mediated pathway arbitrate directly the mechanism of mitophagy [144].
When the IMM becomes depolarized PINK1 is stabilized in the outer mitochondrial membrane
surface, where it recruits the E3 ubiquitin ligase Parkin. Parkin ubiquitinates various substrates in the
outer mitochondrial membrane, includingMFN1 and MFN2, favoring in turn mitophagy of damaged
mitochondria [142,145].
The upstream tumor suppressors STK11/LKB1 (serine/threonine kinase 11) and their target,
AMPK, contribute to HSCs quiescence by directly controlling mitochondrial autophagy, ULK1 and FIS1
mediated [146]. Inside this network, Foxo3a and Tuberous sclerosis 1/2 (TSC1/2), inhibition of the mTOR
pathway, cooperate in the mitophagy process [123]. Lastly, PPARγ activation is crucial to preserve
autophagy initiation, suggesting complex interconnection in HSC mitochondrial dynamics [147].
4. Leukemia Stem Cells Mitochondria: A Vulnerable Dormant Galaxy
Nowadays, leukemic stem cells (LSCs) represent the primary focus in the drug therapy field, since
their targeting could lead to better outcomes as well as disease-free survival [148]. LSC cells are more
resistant to first line therapies and persist over time, by raising the risk of relapse. The debate HCSs
versus LSCs started in 1950 when Warburg and his group defined cancer stem cells (CSC) features,
including anaerobic glycolysis, as the main force to produce ATP, and low-ROS conditions [149,150].
In the last few years, several studies confirmed that CSC uses preferentially OXPHOS [151,152] to
produce energy, but maintains very low ROS levels through sustained mitophagy activation and
significant high activity of the mitochondrial BCL-2 protein [153]. Moreover, it has been remarked that
increased levels of OXPHOS in CSCs can support chemotherapy resistance [154]. Thus, understanding
the unique and vulnerable properties of LSCs metabolic process could contribute to target leukemic
stemness. Going back to the previous chapter, we highlighted that LSCs exhibit peculiar pathways to
preserve their redox state, in order to sustain survival in hypoxic environments and to prevent them
from going into apoptosis. Notably, LSCs display (1) OXPHOS, as a crucial process for cell survival
and maintenance, despite the reduced cellular oxidative status and the inability to employ glycolysis
(2) significant low ROS levels (3) aberrant BCL-2 expression and (4) elevated autophagy activation
(Figure 1).
(1) The OXPHOS process is primarily used by LSCs and this feature could be exploited to target
LSCs. Why LSCs favor OXPHOS instead of glycolysis is not well characterized, and this topic will
represent an important avenue for future investigation. One possibility is that OXPHOS, being a highly
efficient mechanism to produce energy, might be crucial for sustaining LSC energy requirements and
survival [155]. Indeed, a common feature of LSCs is the ability to exploit other metabolic events such
as protein/RNA synthesis, amino acid, and fatty acids metabolism as an essential source for energy
production under metabolic stress conditions. Recent studies confirmed that amino acid and fatty
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acid metabolism (FAO) are altered in AML, heavily impaired LSCs survival when they are inhibited,
and directly contribute to maintaining OXPHOS in LSCs [156,157].Int. J. Mol. Sci. 2020, 21, 3928 13 of 31 
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Progenitor Cells. (A) HSCs exhibit a low energy status, high glycolysis with resultant low ROS and low
adenosine triphosphate (ATP) production. LSCs exhibit a low ROS level but high ATP production due
to activation of oxidative phosphorylation (OxPHOS). Amino acid and fatty aci metabolism heavily
contribute to maintain OXPHOS i LSCs. In co trast, progenitor cells exhibit high mitochondrial
activity, high ROS, nd ATP levels as a result of the OxPHOS process. (B) Hematopoietic stem cells have
small ot chondria, with globular and fragmented shape consistent with increased mitochondrial
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autophagy in o der to efficiently liminate damaged mitoch ndria and r duce ROS levels since the rate
of cellular stress is sustained. In cont st, progenitor cell have mitochondria with elongated and fu ed
shape, consistent increase mitochon rial fusion, and umerous cristae.
Otherwise, leukemia stem cells are more addicted to these processes when compared to the
counterpart HSC. Amino acids are commonly metabolized in the TCA cycle of LSCs derived from de
novo AML patients [158]. Furthermore, targeting amino acid uptake results in decreased OXPHOS
and selective targeting of LSCs. The fact that this pathway was highly sustained in leukemia stem
cells, it represents a suitable druggablity target. Metabolism of specific amino acids including cysteine,
glutamine, and branched-chain amino acids (BCAA) are the most important in the LSC compartment.
Glutamine is converted to glutamate through the enzyme glutaminase (GLS), which was found to
be highly expressed in AML, and subsequently converted to α-KG. The α-KG crucial role in LSCs is
linked to its ability to enhance the reduction of NADP+ to NADPH, which is required for the production
of the antioxidant glutathione (GSH) and, in turn, protects LSC cells by neutralizing reactive oxygen
species [159]. In vitro glutamine deprivation exhibit negative effects that can be rescued by adding
α-KG to the AML cell, suggesting a prominent role of glutamine in LSCs survive [160]. Interestingly,
inhibition of GLS synergized with venetoclax [160].
Cysteine drives energy metabolism in LSCs, since its metabolism mediates the synthesis of
glutathione favoring oxidative phosphorylation and survival of LSCs. The depletion of cysteine targets
directly OXPHOS in LSCs, confirming that LSCs in AML patients rely on amino acid metabolism to fuel
oxidative respiration/phosphorylation [50]. Moreover, targeting amino acid uptake with Venetoclax
(ABT-199), a promising BCL-2 inhibitor, decreased OXPHOS resulting in LSCs killing and achievement
of remission in AML patients [161].
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BCAAs are a group of three essential amino acids leucine, isoleucine, and valine, for which
synthesis is catalyzed by the BCAA transaminases 1 (BCAT1) and 2 (BCAT2). BCAT1 overexpression
seems to be a feature that is LSC specific, and it was associated with a worse prognosis [162]. In vitro
BCAT1 inhibition significantly inhibits primary AML cell proliferation [163].
Similar to amino acid metabolism, FAO is a second important source of NADPH [164]. FAO
directly generates a large number of fatty acyl–derived acetyl-coenzyme A (CoA) to promote the
Krebs cycle and OXPHOS.FAO is involved in the mitochondrial pathways of the TCA [160] cycle and
OXPHOS, where it contributes to the maintenance of self-renewal in LSCs [165,166]. Leukemia stem
cells express a high level of fatty acid transporter CD36 [167]. The CD36+ LSCs exhibit a high level
of FAO, quiescent feature, and chemotherapy resistance [167]. Treatment of LSCs and HSCs with a
PPAR-δ inhibitor reduces stem cell properties HSCs/LSCs, confirming that the FAO process is crucial to
maintain quiescence [168]. The carnitine palmitoyltransferase 1a (CPT1a) is a fatty acid transport that
promotes the entry of fatty acid into the mitochondria matrix, crucial to carry out FAO. In this regard,
a CPT1 inhibitor in combination with venetoclax and 5-azacytidine treatment, directly targets FAO in
functional LSCs, suggesting that FAO at once contributes to LSCs [169]. Recent evidence suggests that
FAO upregulation could contribute to therapy resistance in venetoclax-treated patients [170]. Thereby,
FAO could contribute to a general mechanism in therapy resistance. Indeed, inhibition of fatty acid
transport into the mitochondria leads to increased survival in AML mouse models [171]. Avocatin B,
an avocado-derived compound, was demonstrated to possess potent anticancer activity by selectively
targeting FAO, increasing ROS levels and chemosensitizing AML cells to Ara-C [172].
Finally, another interesting strategy used by LSC to maintain at the same time oxidative
phosphorylation and functional mitochondria is the presence of gap junction (GJ) [173]. These structures
have the ability to regulate leukemic stem/progenitor cell survival, proliferation and self-renewal
by creating a physical interaction between LSCs and Bone Marrow stromal cells (BMSC). This type
of communication creates continuous trafficking of whole functional mitochondria within the high
oxidative stressed LSCs, which undergoes ROS detoxification and acquires the ability to escape
from chemotherapy [173]. Connexins represent the bricks of these GJ and their deregulation has
been associated with the reduction of functional HSCs. Connexin 43 (Cx43) is a crucial regulator
of hematopoiesis and its expression increased in LSCs in order to directly regulate leukemic cells
bioenergetics, energetic balance, and metabolism through functional mitochondria transfer [174].
Interestingly, leukemia cells generated in vitro without mitochondrial DNA (ρ0 cells) are characterized
by a reduction of malignant potentiality, but this feature is completely modified and associated with
leukemic progression when co-cultured with BMSC [175]. Inactivation of this process in a leukemic
context could provide a novel approach in leukemia therapy.
(2) A broad number of recent studies confirmed that LSCs are characterized by a low cellular
oxidative status, (ROS-low), due to enhanced activity in processes including autophagy and antioxidant
machinery [176]. ROS-low cells possessed an engraftment advantage with shorter leukemia-free
survival in transplanted mice. Sorting this ROS-low pool has allowed for observing some exclusive
leukemia stem cell features [177]. LSCs are highly sensitive to increases in ROS levels and showed
a reduced ability to use glycolysis to produce energy. AMPK is important for the survival of LSCs,
where it controls mitochondrial dynamics and ROS level via autophagy ULK1-mediated, by conferring
to LSCs the ability to sustain high mitochondrial stress [178]. AMPK deletion in AML LCS induced
a significant ROS increase in the LSC compartment, followed by an increase in DNA damage and
reduction in glucose flux [179]. Another relevant pathway important for ROS regulation in LSCs is
the glutathione metabolism, a process hyper-activated in AML, whose expression correlates with an
increase in relapsed and refractory AML. Glutathione peroxidase 3 (GPX3) −/−is able to reduce LSCs
via apoptosis, suggesting the importance of this process in LSC behavior [166]. Otherwise, increased
expression of antioxidant enzymes promotes the progression from MDS toward secondary AML [180].
Lastly, HSCs and LSCs are highly sensitive to p53-mediated apoptosis, whose activation is heavily
dependent on oxidative stress and ROS-high level. This implies that the downregulation of p53
Int. J. Mol. Sci. 2020, 21, 3928 13 of 27
response to basal ROS levels is crucial to the maintenance of hematopoietic stem cells pool [181].
Additionally, p53-induced gene 3 (PIG3) is a NADPH-dependent reductase, whose ability to induce
ROS is essential for p53-mediated apoptosis in AML [182].
(3) LSCs have to maintain low ROS levels and high mitochondrial ATP levels, which are essential
to sustain hematological disease. In addition, their mitochondrial membrane potential is reduced
compared to HSCs [153,155]. Thus, the activation of anti-apoptotic responses is crucial to protect them
from oxidative-stress conditions. In this scenario, hyper-activation of BCL-2 and increased autophagy
mechanisms represent the main LSCs weapons, leukemia-specific, and therefore potentially druggable.
BCL-2 inhibitors have proved to be efficient in exploiting ROS-low LSCs [153]. BCL-2 protein is able
to block the apoptotic pathway by preventing oligomerization of BAX and BAK, and subsequently
inducing mitochondrial outer membrane permeabilization. In addition, it is crucial for the OXPHOS
process and for mitochondrial bioenergetics. After BCL-2 inhibitors treatment, ROS levels increased
dramatically inducing apoptosis in almost exclusively LSC compartment [154,183]. Moreover, BCL-2
inhibitor drug Venetoclax associated with 5-azacitidine showed a broad spectrum of activity by
inhibiting amino acid uptake and catabolism, by cooperating in autophagy processes impairment,
thereby providing a molecular mechanism for targeting of LSCs [184].
Mitophagy is a mitochondrial quality control mechanism up-regulated in LSCs population,
in order to efficiently eliminate damaged mitochondria, since oncogenes and high proliferation rate
increase cellular stress. FIS1 comes out as crucial in the mitochondrial fission process and in autophagy
activity to sustain LSCs [179]. In AML, LSC FIS1 expression is increased in comparison to the bulk
of AML cells and to HSCs. Its expression correlates with an increase in AMPK activity, the direct
regulator of FIS1. FIS1 inhibition, as other mitophagy actors’ inactivation, showed in AML cells
a dramatic change in mitochondria morphology associated with a reduction in stem cell potential,
proposing a critical role of mitophagy for sustaining LSCs [179]. Interestingly, higher expression of
FIS1 is associated with increasing the risk of relapse and to chemo-resistance in AML. Notably, these
patients exhibit a significant increase in the frequency of LSCs, thus confirming the pivotal role of
autophagy in leukemia stem cell biology and drug resistance.
5. Mitochondria as Therapeutic “Hot-Spot” in Hematological Malignancies
By reviewing mechanisms of action of chemotherapy and molecular drugs that target mitochondria,
we can indisputably say that most of them accomplish their action by acting on cell death pathways or
cause cell death by disrupting metabolism (Figure 2). On the other hand, anti-apoptotic mechanisms
are upregulated in the majority of hematological neoplasms, especially in those characterized by
abnormal clonal proliferation. This new degree of cell proliferation certainly requires a redistribution of
priorities in cellular metabolism. A milestone scientific discovery is presented in the study by Warburg
et al. where the core discourse was about the increased metabolism of glucose to lactate in malignant
cells to meet the needs for intensive cell growth [69,185]. More or less, the imbalanced cell growth
mechanisms and genetic abnormalities highly present among hematological malignancies can be seen
as potential foci for target treatment possibilities. Namely, AML or CLL may be observed as a role
model to explain how mitochondrial target therapeutic action can be achieved. Here, we present the
most important drug groups, already established or with high potential to be in use in the near future,
through whose action, mitochondrial-targeted therapy can be described. Going into detail, the first
barrier that preserves the integrity of mitochondria is the OMM, defined with selective permeability
and absolute control of what exits and penetrates in and out of the mitochondrial matrix to the cytosol.
The preservation of mitochondrial homeostasis is mainly due to the action of the protein permeability
transition pore complex (PTPC). It is a massive protein structure composed of several parts such as
VDAC located on OMM, adenine nucleotide translocase (ANT) located in IMM, and cyclophilin D
(CYPD) in the mitochondrial matrix. Impairment of the function of any part of the PTPC will lead to
the activation of intrinsic apoptotic pathways and certain cell death. The reported elements make the
mitochondrial membrane barrier one of the first potential therapeutic “hot spots” [186].
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selective permeability and activation of caspase cascade; (2) Hexokinase inhibitors block the enzyme
hexokinase and ADP/ATP production; (3) IDH inhibitors manifest their activity inhibiting the
α-ketoglutarate production in TCA; (4) Impaired OXPHOS and hyperproduction of ROS lead to
cell death; (5) Using BCl-2 family proteins as targeted activation of intrinsic apoptotic pathways through
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A special group of substances called hexokinase (HK) inhibitors II repress the activity of the
enzyme hexokinase, a catalytic enzyme that converts glucose to glucose 6 phosphate. This enzyme is
closely correlated to the cytosolic part of the VDAC/ANT complex and, in addition to energy, together
with the membrane protein complexes, it also has a regulatory function in terms of permeability [187].
It was already described that HK II is overexpressed in cancer cells. Because ANT activity is based on
transferring the ATP molecule out of the mitochondria, blocking hexokinase leads to the cessation of
glycolysis and to the absence of energy molecules transported into the cytosol, i.e., energy deficiency
and cell death. A recent study [188] has explained the in vitro mechanism of two HK inhibitors II,
arabinofuranosyl cytidine (Ara-C), and 2-Deoxy-D-glucose (2-DG). In fact, inhibition of glycolysis
increases the sensitivity of certain AML cell lines (U937, OCI-AML3, THP-1, and KG-1) to Ara-C,
and combinatorial therapy with 2-DG shows a synergistic effect. These positive results will further
deepen scientific research in the field of HK inhibitors as potential pharmacological substances to
target mitochondria. Speaking of AML and metabolic disruption, there are also scientific shreds of
evid nce about the role of mutated IDH in molecular pathogen sis [58,188,189]. The revolutionary
discoveries and recent application of IDH1 and IDH2 i ors in the treat nt of AML, although not
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directly targeted the mitochondrial structures, can still be considered in this light given the role of IDH
isoforms in cellular metabolism [62,190].
Another way to alter mitochondrial metabolism is to inhibit energy production by OXPHOS or
to induce hyperproduction of ROS. Both mechanisms of action will consequently lead to cell death.
In order to avoid the volume of presentation, here we aimed to explain the basic functioning of
this targeted therapy through some examples. Recent scientific research suggests that a complex I
inhibitor—IACS-010759, has shown promising results in the treatment of patients with AML [191].
The realization that a certain type of micro-RNA is overexpressed and correlated with poor prognosis
in some hematological neoplasms, has opened up opportunities to consider this option as a possible
therapeutic approach [192]. By targeting these RNA molecules, it is disabled the translation into
protein product and its implementation in the OXPHOS [193]. Going deeper into the layering of
mitochondria, another protein complex in the IMM is the Bcl-2 family of proteins. Undoubtedly, it is
the most exploited choice of mitochondrial target therapy. A large number of scientific studies are
devoted to the Bcl-2 family of proteins and their role in cancer treatment. Bcl-2 inhibitors are one of the
first in this group, especially used in CLL patients. By binding to the Bcl-2 protein, unpretentiously said,
they block its anti-apoptotic activity or act on a gene/protein expression [194,195]. On the other hand,
similar activity proclaims a group of drugs called BH3 mimetics [196,197]. They prevent the binding
between BH3-only proteins and anti-apoptotic factors. Among these drugs, the most important one is
Venetoclax and its application in CLL patients with 17p deletion, resulting in a loss of the TP53 gene,
enabling the direct apoptotic realization without the presence of p53 [81,184].
Furthermore, Venetoclax was also effective in relapsed/refractory AML patients [198,199].
Konopleva and colleagues report the important results obtained with a phase II trial of venetoclax
monotherapy in a cohort consisting of older high-risk patients. In addition, the high levels of BCL-2
identified in LSCs provide a novel strategy to target the quiescent LSC population, crucial for driving
the progression to AML. However, treatment with Venetoclax reported an increase of resistance
mediated by the upregulation of alternative antiapoptotic proteins [200]. Within this scenario, dual
inhibition seems a very attractive alternative in Venetoclax-resistant AML cells. Overexpression of
mitochondrial protein MCL1, a common feature in hematologic malignancies, was associated with
venetoclax-resistance in AML VU661013, a selective MCL1 inhibitor able to induce apoptosis in
AML cells, overcoming venetoclax resistance [201]. The MAPK pathway directly stabilizes BCL-2
and contributed to developing resistance to Venetoclax [199]. Konopleva et al. confirmed that dual
inhibition venetoclax-cobimetinib (GDC-0973), this latter an allosteric MEK inhibitor, reduced leukemia
burden in vivo xenograft models. A synergistic effect, with astonishing results, was observed in phase I
clinical trial with hypomethylating agents decitabine or 5-azacytidine [202]. This combination achieved
an overall response rate of over 70% in a group of older high-risk patients AML. One potential target
of hypomethylating agents could be p53 itself, or a member of the p53 family.
In this regard, we cannot continue the discussion on apoptosis-cancer therapy unless we take
very careful consideration of the p53 properties—known in the scientific literature as the guardian
of the genome [203,204]. It plays a major role in maintaining the normal dynamics of the cell cycle
and DNA repair. Modern science has no doubt about the enormous impact of mutated p53 alleles on
carcinogenesis. Literature data suggest that almost 50% of all cancers have a mutated p53 gene [205].
There are several ways in which p53 can be targeted as a potential anti-cancer treatment, both in
general and in hematological diseases. Expression of p53 is dependent on MDM-2, a ubiquitin-protein
ligase that stimulates the degradation of the wild-type and mutant p53 genes [206]. Considering the
fact that there is an overexpression of MDM-2 in a large number of leukemias, lowering the level of
MDM-2 will mean favoring cell death [207]. Thus, using targeting therapy that blocks the MDM2–p53
binding will thereby increase the p53 protein levels and promote cancer cell killing activity. Nutlin,
for example, is a drug that exhibits this type of action [208]. The diverse role that p53 plays in apoptotic
pathways, even though it has been a subject of study many decades, has not been adequately explained
yet. p53 achieves its pro-apoptotic role by interacting with pro-apoptotic BH-3 only proteins, especially
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PUMA and NOXA. In addition, p53 in some cases may act as a BH-3 only protein and can directly
activate the apoptosis effectors BAX and BAK [209].
Immunotherapy with p53 is probably the most promising target therapy that has received much
attention in recent years in science. While this idea is not new, there are new ways of thinking about its
implementation. At the core of its creation is the classic method of vaccine, i.e., immune stimulation
with antibodies to the mutant p53 protein. This is quite possible since the mutated p53 protein can
be perceived as an antigen by our immune system which would produce an appropriate antibody.
Although the whole process is far from routine clinical application, it is interesting to mention some
recent studies that presented promising scientific findings [210].
The most profound part of the mitochondria that can serve as a target “hot-spot” is the
mitochondrial genome—mtDNA. Here we are talking about a genome that consists of 27 genes
and the main product of its decoding is the proteins of the respiratory chain. Its activity through
mtDNA is targeted by several pharmacological substances, and, in the therapeutic regimes of AML,
the well-established is bleomycin. Bleomycin exerts its pharmacological action by causing mtDNA
damage [211]. Enzymes that control DNA replication and translation can also serve as a therapeutic
target. The very fact that cancer cells are characterized by abnormal proliferation, and therefore have
intense mitochondrial liveliness, makes this therapeutic approach quite attractive and promising.
6. Conclusions
Here, we painted a picture of the untangled mitochondrial galaxy. The intensive development
of pharmacotherapy in the last few decades has opened new avenues in molecular pharmacology.
Mitochondria are indispensable targets in this dynamic process, as one of the organelles where
pharmacological action can be achieved. Given the role of mitochondria in apoptosis and apoptotic
dysregulation in the course of carcinogenesis, the focus is particularly on their role as a “hot spot” in
targeted cancer chemotherapy. The vital importance of mitochondria to cell life makes any segment of
their activity a possible “dead point” that would endanger the cell’s fate, and the infamous “Perpetuum
mobile” would be turned off. The key message emerging from this review is that leukemia cells,
especially LSC, during disease progression gain the ability to achieve the largest amount of energy
through increasing metabolic plasticity and through a significant microenvironment contribution.
The OXHPOS, amino acid, and fatty acid metabolism help cancer cells to overcome the normal
counterpart. Developing suitable strategies to eradicate LSCs by targeting their vulnerable and unique
metabolic features can be exploited to improve novel therapeutic strategies. Within this scenario,
Bcl-2 inhibitors represent the best novel approach to treat LSCs. However, more and more studies
suggest that inhibition of a single mechanism will not be so efficient, and relapse is almost obvious.
The encouraging results obtained withVenetoclax are most likely dependent on the fact that Bcl-2 seems
to have multifaceted roles, including oxidative respiration, amino acid uptake, fatty acid oxidation, and
apoptosis, all crucial for LSCs survival. Nevertheless, resistance mechanisms leading to the selection of
novel resistant subclones can move researchers to identify novel combined therapy in order to explore
and to target the dynamic leukemic metabolic interplay. Furthermore, peculiar LSCs mitochondrial
characteristics remain to be elucidated, representing an exciting aim for future investigation.
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VDAC Voltage-dependent anion channel
MAM Mitochondria-associated membranes
IMM Inner mitochondrial membrane
RC Respiratory chain
OMM Outer mitochondrial membrane
ETC Electron transport chain
ROS Reactive oxygen species
TCGA Cancer genome atlas
MDS Myelodysplastic syndromes
AML Acute myeloid leukemia
IDH Isocitrate dehydrogenase
α-KG α-ketoglutaric acid
CN-AML Normal cytogenetics AML
COX Cytochrome c oxidase
CLL Chronic lymphocytic leukemia
OMM Outer mitochondriamembrane
HSC Hematopoietic stem cells
OXPHOS Oxidative phosphorylation program
PDK Pyruvate dehydrogenase kinase
HIF-1 Hypoxia inducible factor 1
LDHA Lactate dehydrogenase A
HK1, HK2 Hexokinase 1 and 2
ALD-A, ALD-C Aldolase A and C
ENOalpha Enolase alpha
PGK1 Phosphoglycerate kinase 1
NFR2 Nuclear factor erythroid 2-related factor 2
SODs Superoxide dismutase genes
FoxO3 Forkhead box O3
PTEN Phosphatase and tensin homolog
AMPK 5′ AMP-activated protein kinase
ULK1 Unc-51 like autophagy activating kinase 1
PIP2 Fosfatidilinositolo 4,5-bisfosfato
PIP3 Phosphoinositide-3,4,5-trisphosphate
ATM Ataxia telangiectasia mutated
BID BH3-interacting domain death agonist
Drp1 Dynamin-related protein 1
Fis1 Mitochondrial fission 1 protein
OPA1 Mitochondrial dynamin like GTPase
Atg Autophagy-related genes
PINK1 PTEN-induced putative kinase 1
TSC1/2 Tuberous sclerosis 1/2
PPAR δ Peroxisome proliferator-activated receptor delta
CSC Cancer stem cell
FAO Fatty amino acid metabolism
GLS Enzyme glutaminase
GSH Glutathione
ABT-199 Venetoclax
GPX3 Glutathione peroxidase 3
ANT Adenine nucleotide translocator
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